drug_type
RELEVANT_DRUG
intervention_type
cellular therapy
drug_description
Autologous CD39+CD103+ CD8+ tumor-infiltrating lymphocytes (TIL) enriched and expanded ex vivo (AGX148); adoptive cellular therapy targeting tumor antigens via the TCR.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD39+CD103+ CD8+ TILs are enriched and expanded ex vivo and reinfused to provide tumor‑reactive cytotoxic T cells that recognize patient-specific tumor antigens via their endogenous TCRs and mediate HLA-restricted killing of tumor cells.
drug_name
DP CD8 TIL
nct_id_drug_ref
NCT05902520